Orchid receives USFDA approval for Cephalexin ANDA

New Delhi, July 12 (UNI) Orchid Chemicals and Pharmaceuticals today announced that it has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Cephalexin oral suspension.

Cephalexin is an off-patent molecule that forms part of the company's distribution alliance with US generic pharma major, Par Pharmaceuticals, a company statement said.

Despite the complexity of the formulation, Orchid would have a good positioning in the generics market, the statement added.

Orchid's Cephalexin capsules are already marketed in the US distribution partnership with Par.

With the latest ANDA approval, the number of dosage forms, oral solids and injections distributed by the company in Orchid in the US stands at 12.

UNI DKS ARB PM1823